[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Menarini Silicon Biosystems\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":4},"100636522",false,"NCT07566780","Cell-based Non-invasive Prenatal Test Workflow","Prospective Collection of Maternal Venous Blood Samples for Cell-based Non- Invasive Prenatal Test Workflow","TOTAL#5","Inclusion Criteria:\n\n1. Informed consent signed before any study-specific procedures\n2. Pregnant women with singleton or twin pregnancy, at 8+0 - 14+6 week of gestation, aged ≥18 years\n3. No medical contraindication for collecting 30 ml blood sample\n\nExclusion Criteria:\n\n1. Unable to provide informed consent\n2. Known infections that carry a risk of vertical transmission\n3. Known maternal viral diseases: HIV and HCV, HBV","FEMALE","18 Years",{"count":19,"type":20},1400,"ESTIMATED","OBSERVATIONAL","The aim of this study is to optimize a new non-invasive prenatal screening method based on the capture of fetal cells from maternal blood and to complete its development by obtaining maternal blood samples during the first trimester of pregnancy.",[24],"Pregnant Women","NOT_YET_RECRUITING","2026-04-28",{"date":28,"type":29},"2026-05-05","ACTUAL",{"date":31,"type":20},"2026-05-04",{"date":33,"type":20},"2027-12-31",{"name":35,"class":36},"Menarini Silicon Biosystems","INDUSTRY",""]